224TL, Scientist, Molecular Engineering

Job Code 224TL

Description

Fate Therapeutics is currently seeking a talented and highly motivated molecular biologist with strong genetic engineering background to join a multidisciplinary team dedicated to the discovery of novel cellular therapeutics for the treatment of hematological disorders and solid tumors. The candidate will play a key role in developing and optimizing strategies for engineering multiple cell types including human iPSCs, T cells, and NK cells for derivation of cell therapy products. The candidate must have extensive experience in molecular biology including plasmid design and construction, conventional and real-time PCR, and demonstrated expertise in gene editing. The candidate will also have extensive experience in tissue culture techniques, including mammalian cell culture, transient transfection, virus production and transduction. The position will require innovative thinking, strong independent and collaborative research abilities, and excellent oral and written communication skills. This is a full-time, bench-level position reporting to the Director in Molecular Engineering and is located at the Company’s corporate headquarters in San Diego, California.

Download a PDF of the job description for more details:

View PDF

For consideration send cover letter and curriculum vitae to: careers@fatetherapeutics.com and reference job 224TL.

About Fate Therapeutics, Inc.

Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders. The Company’s cell-based product candidate pipeline is comprised of off-the-shelf immuno-oncology therapeutics, including NK- and T-cell-based candidates derived from induced pluripotent cells, and immuno-regulatory therapeutics, including hematopoietic cell-based candidates for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing auto-reactive T cells of patients with auto-immune disorders. Its adoptive cell therapy candidates are based on the Company’s novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.